The Board of Vigmed Holding AB (publ) has appointed Henrik Olsen as CEO of the
Company. He has since the autumn of 2015 served as the acting CEO of Vigmed.
The decision was made after completion of a thorough evaluation process
including several external candidates in which the Board has found Henrik Olsen
to be the most suitable person to lead the company forward.
“The Board is confident that Henrik Olsen is the right person to lead Vigmed
forward. Since Henrik stepped into the position as acting CEO he has managed to
implement a strong operational leadership and refocused the company into a
market oriented direction which is already yielding results”, commented Chairman
Lennart Holm.
“I am very pleased to have the continued confidence of the Board and look
forward to leading a skilled and motivated Vigmed-team into the market focused
phase we are now entering”, says Henrik Olsen. “We are already seeing some
positive results from our restructuring and have full focus on increasing sales
in all the European markets. We are facing an exciting time full of
opportunities and challenges to overcome” Henrik Olsen continues.
For further information contact:
Chairman of the Board, Lennart Holm +46 70 630 8562 or CEO, Henrik Olsen +46 76
349 7364
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries and the associated risk of cross infections with blood
-borne infectious diseases by offering the market unique needle-protected
products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is
traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has
approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified
Advisor. Additional information about the company can be found on Vigmed’s
website: www.vigmed.com/investor
